Rein Therapeutics Inc. (NASDAQ:RNTX) Stock Has Consensus Price Target of $6.00

Shares of Rein Therapeutics Inc. (NASDAQ:RNTX) have been given an average rating of “Hold” by the four ratings firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and two have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $6.00.

Several research firms have recently issued reports on RNTX. Maxim Group initiated coverage on Rein Therapeutics in a research note on Monday, July 20th. They set a “buy” rating and a $4.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Rein Therapeutics in a research note on Tuesday, August 18th. Finally, Weiss Ratings cut shares of Rein Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st.

Institutional Investors Weigh In On Rein Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of RNTX. Velan Capital Investment Management LP bought a new stake in shares of Rein Therapeutics during the 2nd quarter valued at about $1,768,000. Sigma Planning Corp increased its position in shares of Rein Therapeutics by 41.0% during the first quarter. Sigma Planning Corp now owns 348,677 shares of the company’s stock valued at $453,000 after buying an additional 101,400 shares during the period. Sequoia Financial Advisors LLC purchased a new position in shares of Rein Therapeutics during the second quarter valued at about $260,000. Finally, Chicago Partners Investment Group LLC raised its stake in Rein Therapeutics by 32.2% in the first quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock worth $53,000 after buying an additional 10,000 shares in the last quarter. 90.89% of the stock is owned by hedge funds and other institutional investors.

Rein Therapeutics Stock Performance

Shares of NASDAQ:RNTX opened at $0.67 on Wednesday. The stock’s 50-day moving average is $0.74 and its 200 day moving average is $1.04. Rein Therapeutics has a 1 year low of $0.54 and a 1 year high of $2.10.

Rein Therapeutics (NASDAQ:RNTX) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.17. As a group, analysts forecast that Rein Therapeutics will post -0.47 EPS for the current fiscal year.

Rein Therapeutics Company Profile

Rein Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious pulmonary and fibrotic diseases. The company’s research is centered on therapies intended to address the underlying biological mechanisms that drive tissue scarring and chronic disease progression.

Its lead investigational product is bexotegrast, an oral small-molecule inhibitor of the integrins αvβ1 and αvβ6. Rein Therapeutics is evaluating bexotegrast in clinical development for conditions including idiopathic pulmonary fibrosis, a progressive lung disease, and primary sclerosing cholangitis, a chronic disease that affects the bile ducts and can lead to liver damage.